Avacta Group plc
("Avacta" or the "Group" or the "Company")
Appointment of Joint Broker
LONDON and PHILADELPHIA - February 4, 2025 - Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today announced the appointment of Panmure Liberum Limited ("Panmure Liberum") as its joint broker with immediate effect. Panmure Liberum will work alongside Peel Hunt, the Company's Nominated Adviser and existing corporate broker.
-Ends-
For further information from Avacta, please contact:
|
Avacta Group plc Michael Vinegrad, Group Communications Director |
|
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden / Patrick Birkholm |
|
|
Panmure Liberum (Joint Broker) Emma Earl, Will Goode, Mark Rogers David Cox (Healthcare Specialist Sales) |
|
|
ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor and Communications Contact Renee Leck THRUST Strategic Communications |
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
About Avacta - http://avacta.com/
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.